Hims & Hers Stock Soars on Surprise Partnership with Pharma Giant

A major legal overhang for the telehealth company Hims & Hers has been decisively removed, sending its shares skyrocketing. The resolution of a bitter patent dispute with Novo Nordisk has not only ended litigation but has forged an unexpected commercial alliance, fundamentally altering the firm’s strategic trajectory in the lucrative weight-loss medication market.

A Strategic Pivot from Litigation to Distribution

In a significant reversal, Hims & Hers and the Danish pharmaceutical leader Novo Nordisk have officially settled all pending patent lawsuits. As part of the agreement, Novo Nordisk withdrew its legal complaint. The telehealth provider, in turn, has committed to cease the broad marketing of compounded semaglutid—the active ingredient in the blockbuster drugs Wegovy and Ozempic.

This settlement marks a sharp strategic turn. Previously, the company had capitalized on national supply shortages to offer more affordable, compounded alternatives. That very practice had prompted Novo Nordisk to file its patent infringement lawsuit in early February. Moving forward, Hims & Hers will shift its focus to distributing the FDA-approved brand-name products through its platform, with prices ranging from $149 to $499 per month. Compounded versions will reportedly be reserved only for medically necessary exceptions. For investors, the immediate impact is the complete elimination of a substantial legal risk from the company’s valuation.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Market and Analyst Reaction to the News

The market responded to the diminished uncertainty with forceful buying activity. Investor enthusiasm propelled the stock price upward by more than 40 percent. Trading volume surged to approximately 500 percent above its three-month average, with shares closing near $22.15.

Wall Street analysts were quick to adjust their outlooks following the announcement. Needham upgraded its rating on the stock from “Hold” to “Buy,” establishing a new price target of $30. Citigroup also adopted a more constructive view, moving its recommendation from “Sell” to “Neutral” and raising its target to $24.

The company’s financial foundation now appears more robust, supported by an expected price-to-earnings ratio below 20 for fiscal year 2026 and a recently reported quarterly revenue growth exceeding 28 percent. This is further bolstered by an ongoing $250 million share repurchase program. Investor attention now turns to the operational execution of the new distribution model for the original weight-loss medications, set to begin at the end of March.